Asset
Ifidancitinib
Aclaris Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03495817 | phase2 | completed | 2018-03-22 | 2019-10-15 | Aclaris Therapeutics, Inc. | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
| NCT03468855 | phase2 | completed | 2018-03-19 | 2019-10-16 | Aclaris Therapeutics, Inc. | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo |
| NCT03585296 | phase2 | completed | 2018-07-10 | 2019-04-25 | Aclaris Therapeutics, Inc. | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis |
| NCT03551821 | phase2 | completed | 2018-04-11 | 2018-11-06 | Aclaris Therapeutics, Inc. | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata |
| NCT03315689 | phase2 | completed | 2017-12-14 | 2019-06-20 | Aclaris Therapeutics, Inc. | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) |
FDA applications (0)
This company has no applications containing this asset.